Health care stocks were higher Monday afternoon, with the NYSE Health Care Index up 0.4% and the Health Care Select Sector SPDR Fund (XLV) adding 0.6%
The iShares Biotechnology ETF (IBB) fell 1.1%.
In corporate news, AbbVie (ABBV) said it struck a licensing deal with Danish biotechnology company, Gubra, to develop a potential candidate for obesity treatment. AbbVie shares rose 1%.
Pliant Therapeutics (PLRX) shares fell 52% after it said it has ended its Beacon-IPF phase 2b trial of bexotegrast in idiopathic pulmonary fibrosis after an independent review found an imbalance in IPF-related adverse events between treatment and placebo groups.
TG Therapeutics' (TGTX) shares jumped past 18% after it reported Q4 net income of $0.15 per diluted share, swinging from a loss of $0.10 a year earlier.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。